Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People In Brief

This article was originally published in The Gray Sheet

Executive Summary

Digene hires new chief: Daryl Faulkner succeeds Evan Jones in the top spot at papillomavirus test manufacturer Digene, effective Dec. 11. Faulkner will be tasked with expanding the firm's product portfolio beyond its flagship HPV test through R&D, in-licensing and acquisitions. As VP-general manager at Invitrogen, Faulkner helped grow the business to more than $1 bil. in annual revenues. Digene founder Jones, who in June announced plans to retire after 16 years as CEO, will continue to serve on the board of directors (1"The Gray Sheet" June 12, 2006, In Brief)...

You may also be interested in...



Digene Will Achieve Strategic Goals Faster Through Qiagen Merger, CEO Says

Human papillomavirus test maker Digene will expand its international presence and gain critical mass to help counter looming competition in the lucrative HPV test market by merging with Dutch molecular diagnostics firm Qiagen

Digene Will Achieve Strategic Goals Faster Through Qiagen Merger, CEO Says

Human papillomavirus test maker Digene will expand its international presence and gain critical mass to help counter looming competition in the lucrative HPV test market by merging with Dutch molecular diagnostics firm Qiagen

Digene CEO departing

Firm announces upcoming retirement of co-founder and CEO Evan Jones June 8. Having been at the helm for 16 years - from the company's inception through commercialization of its hc2 High-Risk HPV DNA Test, which has captured about 17% of the U.S. cervical cancer screening market - Jones will continue to serve as a board member...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024213

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel